Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Preferred Stock Liabilities (2020 - 2021)

Rani Therapeutics Holdings (RANI) has 2 years of Preferred Stock Liabilities data on record, last reported at $191.0 million in Q2 2021.

  • For Q2 2021, Preferred Stock Liabilities rose 65.39% year-over-year to $191.0 million; the TTM value through Jun 2021 reached $191.0 million, up 65.39%, while the annual FY2020 figure was $184.7 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $191.0 million in Q2 2021 per RANI's latest filing, roughly flat from $191.0 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $191.0 million in Q1 2021 and bottomed at $115.5 million in Q2 2020.